Therapeutic vaccines are products that treat existing diseases or conditions. The primary technology involved stimulates natural mechanisms of the immune system to overpower the infection or disease. In this sense, they are considered therapies, not preventive agents.
A period of dynamic growth in the therapeutic vaccines market is expected with the rollout of some 20 products before 2010 not only to treat cancer, but also to address cocaine and nicotine addiction. Various approaches are being used to develop vaccines that boost the immune response to cancerous cells. Further back in the pipeline, therapeutic vaccines also are in development to treat acquired immune deficiency syndrome (AIDS), autoimmune diseases, neurological diseases and other conditions.
This BCC study provides a comprehensive analysis of available and emerging therapeutic vaccines. It details a range of information, from product analyses through industry trends, and quantifies and qualifies what is expected to become an explosive market within the next decade. Forecasts of product categories are provided for the worldwide market and revenue algorithms are presented, where reasonable, for the U.S. market. Forecasts of cancer vaccines by the type of cancer targeted also are given. They are gleaned from industry sources, as well as from considered assessments of available and emerging technologies.
The report contains:
- An emphasis on companies poised to introduce products during the forecast period
- Analysis of how these introductions will play out in terms of the competitive environment
- Focus on how new products and technologies are likely to define market leaders in the therapeutic vaccine arena
- Forecasts by product segment and indications through 2010, including supporting analyses
- Profiles of companies projected to have therapeutic vaccine products on the market during the period.
The base year for this study is 2004. Market figures are based on revenues at the manufacturers' level and are projected at 2004-dollar value (i.e., inflation is not computed into the projection figures).
Information to prepare this report was obtained from participating and emerging companies in the area of vaccines, industry analysts, health care personnel, the National Institute of Allergy and Infectious Diseases, the Centers for Disease Control and Prevention, the World Health Organization (WHO) and other government agencies, literature searches, annual reports, 10Ks and product literature.
Report Code: BIO052A, Published: March 2005, Analyst: Lynn Gray
